Bigfoot picks Abbott glucose sensor for insulin delivery tech

diabetes devices
Abbott's Freestyle Libre

Abbott has struck a deal to combine its FreeStyle Libre glucose sensing technology with Bigfoot Biomedical’s experimental insulin delivery device. The agreement sets Bigfoot up to start a pivotal trial of a version of its delivery system that incorporates the Abbott technology next year. 

FreeStyle Libre consists of a wearable sensor and handheld reader. Scanning the sensor delivers a glucose reading. Bigfoot’s smartphone app will take the glucose data and turn them into insulin dosing recommendations or use them to trigger automatic deliveries from its pump device. 

Bigfoot devices trialed to date have incorporated the Dexcom G5 continuous glucose monitoring system. Dexcom and Bigfoot teamed up to combine their technologies in 2015. But with Abbott’s device freeing users from the need to calibrate the sensor with finger pricks, Bigfoot has struck a deal to use the FreeStyle Libre technology in all the insulin delivery systems it sells in the U.S.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

A pivotal trial stands between Bigfoot and those sales. Bigfoot plans to start trialing a version of its system incorporating the Abbott technology next year, setting it up to bring the product to market by 2020, according to the Chicago Tribune. Bigfoot had previously said it planned to file for FDA approval early in 2018. 

Abbott is also yet to win FDA approval for FreeStyle Libre; a decision is pending. But as the FDA will assess Bigfoot’s insulin delivery system as a whole, the startup could in theory bring its device to market before Abbott gets a green light. 

Bigfoot has spent the past two years preparing for the anticipated introduction of its device by raising $35.5 million in a series A round, running a clinical trial and acquiring the developers of insulin pumps and pens. The Abbott agreement builds on these earlier deals. 

“A no-calibration glucose sensor is the final piece of the puzzle needed to enable consumer-friendly and accessible integrated insulin delivery systems,” Bigfoot CEO Jeffrey Brewer said in a statement. 

Suggested Articles

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Exact Sciences received an FDA breakthrough designation for its liver cancer blood test as it finalized its $2.8 billion merger with Genomic Health.